Updates on the Medical and Surgical Management of Gastrointestinal Diseases

J6739

Gastrointestinal diseases affect an estimated 60 to 70 million U.S. citizens annually.

This course will provide an overview of the latest issues in clinical gastroenterology and hepatology, including issues related to COVID-19.

Upon completion of this program, course participants should demonstrate comprehensive knowledge of critical issues in gastroenterology including the COVID-19 pandemic and IBD, sacral nerve stimulation, anastomoses in Crohn’s disease, surgical issues pertinent to the colorectal cancer management, cirrhosis/liver transplant, management of fatty liver, eosinophilic esophagitis, fecal incontinence and gastroparesis.

• Gastroenterologists
• Internal medicine physicians
• Family physicians
• Physician assistants
• Nurse practitioners and nurses

Miguel Regueiro, MD
Chair, Digestive Disease and Surgery Institute
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University

• 12:30 p.m. | Sign In/Visit Exhibitors
• 12:50 p.m. | Welcoming Remarks
  Kofi Clarke, MD, FACP, FRCP (Lond.) AGAF
  Walter A. Koltun, MD, FACS, FASCRS

Inflammatory Bowel Disease

• 1 p.m. | Biosimilars in IBD
  Emmanuelle D. Williams, MD

  Objectives

  • Distinguish Biological versus Biosimilar IBD therapies.
  • Review the evaluation of Biosimilars.
  • Apply known data of Biosimilars to patient care.
• 1:30 p.m. | New Therapies in IBD
  Matthew Coates, MD, PhD

  Objectives

  • Discuss novel medical treatments for inflammatory bowel disease patients that are currently being developed or tested.
  • Compare the design and effects of these new therapies to those of established medications.
• 2 p.m. | COVID-19 and IBD – What did we learn?
  Miguel Regueiro, MD

  Objectives

  • Explain the management of IBD in patients infected with SARS-CoV-2 (COVID-19).
  • Outline the impact of COVID-19 on the GI tract.
• 2:30 p.m. | Break/Visit Exhibitors

Hepatology

• 2:45 p.m. | Managing Cirrhosis Complications: I’m a great provider, but am I providing high-quality care to my liver patients?
  Alison Faust, MD, MHS

  Objectives

  • Review the evidence-based treatments for complications of cirrhosis.
  • Discuss current compliance with evidence based recommendations in cirrhosis and its impact on clinical outcomes.
• 3:15 p.m. | Nutrition and Frailty in Cirrhosis/Liver Transplant
  Andres Duarte-Rojo, MD, PhD

  Objectives

  • Identify methods to assess malnutrition and frailty in patients with advanced liver disease.
  • Describe how malnutrition and frailty affect clinical outcomes in advanced liver disease.
  • Develop an action plan to counterbalance malnutrition and frailty, and relate the potential impact on clinical outcomes.
• 3:45 p.m. | Riding the post-COVID-19 NAFLD wave: The importance of new lifestyle modifications and drug therapies
  Jonathan Stine, MD

  Objectives

  • Outline the impact of COVID-19 on the prevalence and clinical care of patients with NAFLD.
  • Discuss new evidence for the importance of lifestyle modification in patients with NAFLD.
  • Review emerging drug therapies that may soon be available to treat nonalcoholic fatty liver disease.
• 4:15 p.m. | Adjourn/Visit Exhibitors

• 7:30 a.m. | Sign In/Visit Exhibitors
• 7:50 a.m. | Welcoming Remarks
  Kofi Clarke, MD, FACP, FRCP (Lond.) AGAF
  Walter A. Koltun, MD, FACS, FASCRS

Motility/EoE

• 8 a.m. | What’s New in the Diagnosis and Management of EoE
  Meeta Desai, MD

  Objectives

  • Discuss non-invasive tests that could be used to monitor disease activity in patients with eosinophilic esophagitis.
  • Review novel targeted therapeutics for the treatment of refractory eosinophilic esophagitis.
• 8:30 a.m. | Fecal Incontinence: Diagnosis and Management
  Asyia S. Ahmad, MD, MPH

  Objectives

  • Describe common non-surgical conservative therapies for fecal incontinence.
  • Identify patients with fecal incontinence who could benefit from biofeedback.
• 9 a.m. | Gastroparesis: Current and Emerging Therapies
  Sanam Razeghi, MD

  Objectives

  • Review currently available therapies for gastroparesis.
  • Explore new and novel therapies for gastroparesis.
• 9:30 a.m. | Break/Visit Exhibitors

Surgical Treatment of Colorectal Diseases

• 9:45 a.m. | To cut or not to cut: The management of colon vs. rectal cancer
  N. Arjun Jeganathan, MD, FACS

  Objectives

  • Discuss the surgical management of colon cancer.
  • Discuss the non-surgical management of rectal cancer.
• 10:15 a.m. | Does the type of anastomosis affect Crohn’s disease recurrence?
  Jeffrey Scow, MD, FACS

  Objectives

  • Describe the different type of anastomoses and indications for each.
  • Describe the role of the mesentery in recurrence of Crohn’s disease.
• 10:45 a.m. | Sacral Nerve Stimulation: Which patients benefit?
  Michael Deutsch, MD

  Objectives

  • Identify signs of fecal incontinence and patient selection factors in management strategies.
• 11:15 a.m. | Adjourn/Visit Exhibitors

Kofi Clarke, MD, FACP, FRCP (Lond.) AGAF
Course Director
Professor of Medicine
Chief, Gastroenterology and Hepatology
Penn State College of Medicine

Walter A. Koltun, MD, FACS, FASCRS
Course Director
Professor of Surgery
Director, Penn State IBD Center
Chief, Colon and Rectal Surgery
Peter and Marshia Carlino Chair in IBD
Penn State College of Medicine

Meeta R. Desai, MD
Assistant Professor of Medicine
Division of Gastroenterology and Hepatology
Penn State College of Medicine

Alison Faust, MD, MHS
Associate Professor of Medicine
Division of Gastroenterology and Hepatology
Penn State College of Medicine

Mary R. Maiolo
Administrative Associate
Division of Gastroenterology and Hepatology
Penn State College of Medicine

Asyia Ahmad MD, MPH
Professor of Medicine
Drexel University College of Medicine
Medical Director, GI Division
Tower Health Medical Group

Andres Duarte-Rojo, MD, PhD
Transplant Hepatology
University of Pittsburgh Medical Center

Matthew D. Coates, MD, PhD
Associate Professor of Medicine and Pharmacology
Director of Research, Division of Gastroenterology and Hepatology
Penn State College of Medicine

Meeta R. Desai, MD
Assistant Professor of Medicine
Division of Gastroenterology and Hepatology
Penn State College of Medicine

Michael Deutsch, MD
Assistant Professor of Surgery
Division of Colon and Rectal Surgery
Penn State College of Medicine

Alison Faust, MD, MHS
Associate Professor of Medicine
Division of Gastroenterology and Hepatology
Penn State College of Medicine

N. Arjun Jeganathan, MD, FACS
Assistant Professor of Surgery
Division of Colon and Rectal Surgery
Penn State College of Medicine

Sanam D. Razeghi, MD
Assistant Professor of Medicine
Division of Gastroenterology and Hepatology
Penn State College of Medicine

Jeffrey Scow, MD, FACS
Assistant Professor of Surgery
Division of Colon and Rectal Surgery
Penn State College of Medicine

Jonathan G. Stine, MD
Assistant Professor of Medicine
Division of Gastroenterology and Hepatology
Penn State College of Medicine

Emmanuelle D. Williams, MD
Associate Professor of Medicine
Division of Gastroenterology and Medicine
Penn State College of Medicine

AMA

Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Penn State College of Medicine designates this live activity for a maximum of 6 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses using AMA credit

Nurses will receive a certificate from Penn State College of Medicine verifying their participation in 6 hours of approved continuing medical education. Continuing education activities which are approved by accredited institutions of higher education and that are relevant to patient care or professional nursing meet the requirements of mandatory continuing education for registered nurses in Pennsylvania, as required by the Pennsylvania State Board of Nursing. The Board of Nursing recommends that nurses retain their certificates for a period of at least five years. Additional information is available through the State Board of Nursing website.

These credits meet the criteria set by the ANCC, American Nurses Credentialing Center as contact hours that are acceptable for renewal certification. Additional information is available through the American Nurses Credentialing Center.

ABCGN

According to the criteria of the American Board of Certification for Gastroenterology Nurses (ABCGN), the approved hours in this activity are considered GI Specific for the purpose of recertification by contact hours through the ABCGN.

There is no fee for this activity, but registration is required.

A completed evaluation is required in order to receive a certificate for attending this activity. Please complete and submit the evaluation within the specified time frame.

The University reserves the right to cancel or postpone any course or activity because of insufficient enrollment or other unforeseen circumstances. If a program is canceled or postponed, the University will refund any program registration fees paid but cannot be held responsible for any related costs, charges or expenses, including cancellation/change charges assessed by airlines or travel agencies.

Program registrants who are experiencing illness or have been exposed to anyone who is ill should contact the Continuing Education office before attending any in-person activities.

Content and speakers for all programs are subject to change. Registrants will be notified of any significant updates.

On-campus educational activities provided by Penn State College of Medicine Continuing Education are required to follow healthcare facility guidelines. Off-campus events provided by Penn State College of Medicine Continuing Education follow the COVID-19 requirements of that venue. We ask that all participants respect that some attendees may still choose to wear masks for activities. Check the venue website for the latest requirements and recommendations. Please do not attend this activity if you have symptoms or have been exposed to someone with COVID-19. By attending the activity, you attest that you do not have any symptoms suggestive of COVID-19, which may include fever, cough, shortness of breath, sore throat, loss of taste, loss of smell or any other sign of illness.

Penn State encourages people with disabilities to participate in its programs and activities. Participants who anticipate needing any type of special accommodation or who have questions about the physical access provided should contact the Continuing Education office at least one week in advance of participation or visit.

It is Penn State policy to ensure balance, independence, objectivity and scientific rigor in all educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to mitigate any conflict of interest. Complete faculty disclosure will be provided to program participants at the beginning of the activity.

This publication is available in alternative media on request. The Pennsylvania State University is committed to the policy that all persons shall have equal access to programs, facilities, admission and employment without regard to personal characteristics not related to ability, performance or qualifications as determined by University policy or by state or federal authorities. It is the policy of the University to maintain an academic and work environment free of discrimination, including harassment. The Pennsylvania State University prohibits discrimination and harassment against any person because of age, ancestry, color, disability or handicap, genetic information, national origin, race, religious creed, sex, sexual orientation, gender identity or veteran status and retaliation due to the reporting of discrimination or harassment. Discrimination, harassment or retaliation against faculty, staff or students will not be tolerated at The Pennsylvania State University. Direct all inquiries regarding the Nondiscrimination Policy to the Affirmative Action Director, The Pennsylvania State University, 328 Boucke Building, University Park, PA 16802-5901; 814-863-0471 (TTY). US M.Ed. J6739